Highlights from the Week of 02nd November – 09th November in the world of pharma and healthcare!

Highlights from the Week of 02nd November 2026 - 09th November 2026 ( FDA, Accelerated Approval ) FDA grants accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, 160 mg/2,000 units per mL, SC injection to treat adults with recurrent or metastatic HNSCC ( Health Canada, Approval ) Health Canada authorizes Moderna's mFLUSIVA to treat influenza and mCOFLU, a combined influenza and COVID-19 mRNA vaccine, both for adults aged 50 years and older ( NMPA, Approval ) NMPA of China grants approval to Bayer's sevabertinib to treat adults with unresectable, locally advanced, or metastatic NSCLC with HER2-activating mutations ( FDA, Priority Review ) FDA accepts BeOne's sNDA, BRUKINSA, for Priority Review in combination with rituximab for the treatment of adults with untreated MCL Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Connect with us

Please fill in the information below, and we'll get back to you.